Wuhan Keqian Biology Co Ltd
Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. The company offers vaccines for pigs, poultry, and pets, as well as diagnostic reagents. Wuhan Keqian Biology Co.,Ltd was founded in 2001 and is based in Wuhan, China.
Wuhan Keqian Biology Co Ltd (688526) - Total Liabilities
Latest total liabilities as of September 2025: CN¥580.21 Million CNY
Based on the latest financial reports, Wuhan Keqian Biology Co Ltd (688526) has total liabilities worth CN¥580.21 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Wuhan Keqian Biology Co Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Wuhan Keqian Biology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Wuhan Keqian Biology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Wuhan Keqian Biology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dodla Dairy Limited
NSE:DODLA
|
India | ₹4.01 Billion |
|
Suzhou Huazhijie Telecom Co
SHG:603400
|
China | CN¥631.68 Million |
|
SS Innovations International Inc.
PINK:SSII
|
USA | $23.92 Million |
|
Yunnan Tourism Co Ltd
SHE:002059
|
China | CN¥1.83 Billion |
|
SK Discovery Co Ltd
KO:006125
|
Korea | ₩8.93 Trillion |
|
Jamna Auto Industries Limited
NSE:JAMNAAUTO
|
India | ₹4.28 Billion |
|
Shijiazhuang Kelin Elec Co
SHG:603050
|
China | CN¥3.11 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Wuhan Keqian Biology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Wuhan Keqian Biology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Wuhan Keqian Biology Co Ltd (2016–2024)
The table below shows the annual total liabilities of Wuhan Keqian Biology Co Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥552.80 Million | -33.68% |
| 2023-12-31 | CN¥833.59 Million | -6.51% |
| 2022-12-31 | CN¥891.63 Million | +56.04% |
| 2021-12-31 | CN¥571.41 Million | +42.00% |
| 2020-12-31 | CN¥402.40 Million | +59.38% |
| 2019-12-31 | CN¥252.48 Million | -28.58% |
| 2018-12-31 | CN¥353.51 Million | +36.57% |
| 2017-12-31 | CN¥258.86 Million | +44.61% |
| 2016-12-31 | CN¥179.01 Million | -- |